Amicus Therapeutics Inc (FOLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($16.25 Million) by net assets ($274.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Amicus Therapeutics Inc for the company's overall valuation and market capitalisation.
Amicus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Amicus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amicus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicus Therapeutics Inc ranked by their cash flow conversion efficiency. Explore FOLD cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crescent Energy Co
NYSE:CRGY
|
0.137x |
|
Beijing Roborock Technology Co Ltd
SHG:688169
|
-0.014x |
|
MGM China Holdings Limited
F:M04
|
0.568x |
|
Fujian Funeng Co Ltd
SHG:600483
|
0.072x |
|
Sweco AB (publ)
ST:SWEC-B
|
-0.005x |
|
BARRATT DEVEL. UNSP.ADR/2
F:3BAA
|
N/A |
|
ALMONTY INDUSTRIES CDIS/1
F:ALI0
|
-0.035x |
|
Insight Enterprises Inc
NASDAQ:NSIT
|
0.013x |
Annual Cash Flow Conversion Efficiency for Amicus Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Amicus Therapeutics Inc from 2005 to 2025. View FOLD share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $274.24 Million | $33.15 Million | 0.121x | +169.20% |
| 2024-12-31 | $194.04 Million | $-33.89 Million | -0.175x | +59.51% |
| 2023-12-31 | $160.17 Million | $-69.09 Million | -0.431x | +68.14% |
| 2022-12-31 | $123.05 Million | $-166.57 Million | -1.354x | -105.49% |
| 2021-12-31 | $307.37 Million | $-202.49 Million | -0.659x | +19.13% |
| 2020-12-31 | $286.38 Million | $-233.29 Million | -0.815x | -54.98% |
| 2019-12-31 | $476.43 Million | $-250.42 Million | -0.526x | +39.91% |
| 2018-12-31 | $342.91 Million | $-299.95 Million | -0.875x | -43.23% |
| 2017-12-31 | $352.85 Million | $-215.49 Million | -0.611x | -46.11% |
| 2016-12-31 | $360.15 Million | $-150.53 Million | -0.418x | -45.18% |
| 2015-12-31 | $347.83 Million | $-100.14 Million | -0.288x | +31.92% |
| 2014-12-31 | $122.18 Million | $-51.67 Million | -0.423x | +57.75% |
| 2013-12-31 | $45.75 Million | $-45.79 Million | -1.001x | -105.33% |
| 2012-12-31 | $69.22 Million | $-33.74 Million | -0.487x | +70.81% |
| 2011-12-31 | $29.59 Million | $-49.42 Million | -1.670x | -675.56% |
| 2010-12-31 | $64.93 Million | $-13.98 Million | -0.215x | +64.33% |
| 2009-12-31 | $71.83 Million | $-43.37 Million | -0.604x | -16.36% |
| 2008-12-31 | $71.04 Million | $-36.86 Million | -0.519x | -452.81% |
| 2007-12-31 | $103.30 Million | $15.19 Million | 0.147x | -66.36% |
| 2006-12-31 | $-77.52 Million | $-33.89 Million | 0.437x | -13.57% |
| 2005-12-31 | $-35.83 Million | $-18.12 Million | 0.506x | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more